Predictive and Prognostic Biomarkers for Colorectal Cancer
- 29 December 2012
- book chapter
- Published by Springer Science and Business Media LLC
Abstract
No abstract availableKeywords
This publication has 100 references indexed in Scilit:
- BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancerBritish Journal of Cancer, 2011
- DNA methylation predicts recurrence from resected stage III proximal colon cancerCancer, 2010
- Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With CetuximabJAMA, 2010
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisThe Lancet Oncology, 2010
- Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximabEuropean Journal of Cancer, 2010
- BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients’ outcomeBritish Journal of Cancer, 2010
- Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patientsBritish Journal of Cancer, 2008
- CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancerNature Genetics, 2006
- RAF/RAS oncogenes and mismatch-repair statusNature, 2002
- Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma: influence of tumour site, stage, adjuvant chemotherapy and type of mutationEuropean Journal of Cancer, 2000